Intracytoplasmic Morphologically-Selected Sperm Injection (IMSI)
IMSI is similar to ICSI with the exception of being able to see sperm at 6000x magnification rather than the conventional 600x with ICSI. Digital magnification enables us to see sperm at extremely high magnification. This enables embryologists to be able to potentially identify sperm defects that may not be visible with conventional ICSI.
Who might benefit?
Published data suggest that 3 groups of patients may benefit from the increased selection of sperm that IMSI offers. These groups are:
- Men with elevated sperm DNA fragmentation levels
- Men with very poor sperm morphology (very high levels of abnormal sperm)
- Couples who have had a previous failed ICSI cycle
As IMSI published data isn’t strong and there isn’t a strong randomized controlled trial (RCT) which is the gold standard for research we don’t charge for it. Performing IMSI will be at the discretion of the embryologists when observing sperm quality or sperm DNA fragmentation data. There is no downside or extra risks to doing IMSI so we will consider its use when we think there may be a patient-specific benefit.